Premium
UMBRALISIB AND CARFILZOMIB POTENTLY INHIBIT CAP DEPENDENT TRANSLATION IN LYMPHOMA
Author(s) -
Pal I.,
Sardinha A.G.,
Scotto L.,
Mundi P.S.,
O'Connor O.A.,
Deng C.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.193_2631
Subject(s) - carfilzomib , eif4e , cancer research , idelalisib , pi3k/akt/mtor pathway , lenalidomide , mantle cell lymphoma , protein kinase b , initiation factor , pomalidomide , kinase , eukaryotic translation , proteasome inhibitor , chemistry , pharmacology , biology , signal transduction , lymphoma , microbiology and biotechnology , proteasome , ibrutinib , multiple myeloma , translation (biology) , immunology , biochemistry , leukemia , chronic lymphocytic leukemia , gene , messenger rna
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom